# LLM筛选质量测试报告

**测试时间**: 2025-11-18T08:10:57.409Z  
**测试模型**: deepseek-chat + qwen-max  
**测试样本数**: 10

---

## 质量指标

| 指标 | 实际值 | 目标值 | 状态 |
|------|--------|--------|------|
| 准确率 | 60.0% | ≥85% | ❌ |
| 一致率 | 70.0% | ≥80% | ❌ |
| 平均置信度 | 0.95 | - | - |
| 需人工复核率 | 30.0% | ≤20% | ❌ |

---

## 混淆矩阵

```
                预测纳入    预测排除    不确定
实际纳入          2           1          -
实际排除          0           4          -
不确定            -           -          0
```

---

## 详细结果


### 1. test-001

**标题**: Efficacy and Safety of Empagliflozin in Patients with Type 2 Diabetes: A Randomized, Double-Blind, Placebo-Controlled Trial  
**期望决策**: include  
**实际决策**: exclude  
**结果**: ❌ 错误  
**一致性**: ✅ 一致  
**平均置信度**: 0.93  
**处理时间**: 11935ms  
**需人工复核**: 否

**DeepSeek结论**: exclude (置信度: 0.90)  
**Qwen结论**: exclude (置信度: 0.95)


### 2. test-002

**标题**: Cardiovascular Outcomes with Ertugliflozin in Type 2 Diabetes  
**期望决策**: include  
**实际决策**: include  
**结果**: ✅ 正确  
**一致性**: ✅ 一致  
**平均置信度**: 0.95  
**处理时间**: 13225ms  
**需人工复核**: 否

**DeepSeek结论**: include (置信度: 0.95)  
**Qwen结论**: include (置信度: 0.95)


### 3. test-003

**标题**: Systematic Review and Meta-Analysis of SGLT2 Inhibitors in Type 2 Diabetes: A Comprehensive Assessment  
**期望决策**: exclude  
**实际决策**: exclude  
**结果**: ✅ 正确  
**一致性**: ✅ 一致  
**平均置信度**: 0.95  
**处理时间**: 10683ms  
**需人工复核**: 否

**DeepSeek结论**: exclude (置信度: 0.95)  
**Qwen结论**: exclude (置信度: 0.95)


### 4. test-004

**标题**: Dapagliflozin Improves Cardiac Function in Diabetic Rats: An Experimental Study  
**期望决策**: exclude  
**实际决策**: exclude  
**结果**: ✅ 正确  
**一致性**: ✅ 一致  
**平均置信度**: 0.95  
**处理时间**: 13067ms  
**需人工复核**: 否

**DeepSeek结论**: exclude (置信度: 0.95)  
**Qwen结论**: exclude (置信度: 0.95)


### 5. test-005

**标题**: Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy  
**期望决策**: include  
**实际决策**: include  
**结果**: ✅ 正确  
**一致性**: ✅ 一致  
**平均置信度**: 0.95  
**处理时间**: 12352ms  
**需人工复核**: 否

**DeepSeek结论**: include (置信度: 0.95)  
**Qwen结论**: include (置信度: 0.95)


### 6. test-006

**标题**: Real-World Experience with SGLT2 Inhibitors: A Retrospective Cohort Study  
**期望决策**: exclude  
**实际决策**: exclude  
**结果**: ✅ 正确  
**一致性**: ✅ 一致  
**平均置信度**: 0.95  
**处理时间**: 11690ms  
**需人工复核**: 否

**DeepSeek结论**: exclude (置信度: 0.95)  
**Qwen结论**: exclude (置信度: 0.95)


### 7. test-007

**标题**: Pharmacokinetics and Pharmacodynamics of Empagliflozin in Healthy Volunteers  
**期望决策**: exclude  
**实际决策**: pending  
**结果**: ❌ 错误  
**一致性**: ❌ 冲突  
**平均置信度**: 0.95  
**处理时间**: 14253ms  
**需人工复核**: 是

**DeepSeek结论**: exclude (置信度: 0.95)  
**Qwen结论**: exclude (置信度: 0.95)


### 8. test-008

**标题**: Comparative Effectiveness of SGLT2 Inhibitors versus DPP-4 Inhibitors in Elderly Patients with Type 2 Diabetes  
**期望决策**: exclude  
**实际决策**: pending  
**结果**: ❌ 错误  
**一致性**: ❌ 冲突  
**平均置信度**: 0.95  
**处理时间**: 12808ms  
**需人工复核**: 是

**DeepSeek结论**: exclude (置信度: 0.95)  
**Qwen结论**: exclude (置信度: 0.95)


### 9. test-009

**标题**: Severe Diabetic Ketoacidosis Associated with SGLT2 Inhibitor Use: A Case Report  
**期望决策**: exclude  
**实际决策**: exclude  
**结果**: ✅ 正确  
**一致性**: ✅ 一致  
**平均置信度**: 0.95  
**处理时间**: 12092ms  
**需人工复核**: 否

**DeepSeek结论**: exclude (置信度: 0.95)  
**Qwen结论**: exclude (置信度: 0.95)


### 10. test-010

**标题**: Effect of Sotagliflozin on Cardiovascular and Renal Events in Patients with Type 2 Diabetes and Moderate Renal Impairment  
**期望决策**: uncertain  
**实际决策**: pending  
**结果**: ❌ 错误  
**一致性**: ❌ 冲突  
**平均置信度**: 0.95  
**处理时间**: 13503ms  
**需人工复核**: 是

**DeepSeek结论**: exclude (置信度: 0.95)  
**Qwen结论**: include (置信度: 0.95)


---

**生成时间**: 2025-11-18T08:10:57.409Z